Astellas Pharma Inc. et al. v. Various ANDA Filers

Case Overview and Background

This litigation represents a crucial front in the ongoing battle over generic competition for the blockbuster prostate cancer drug Xtandi® (enzalutamide). The plaintiffs are the brand-name pharmaceutical companies Astellas Pharma Inc., a Japanese multinational, and its partner Medivation Prostate Therapeutics LLC, a subsidiary of Pfizer, Inc. These operating companies are defending their market exclusivity for Xtandi® against various generic drug manufacturers, known as ANDA filers, who have submitted Abbreviated New Drug Applications (ANDAs) to the FDA seeking approval to market generic versions of the drug before the expiration of the patents-in-suit. The core of the dispute lies in the defendants' "Paragraph IV" certifications, which assert that the patents listed in the FDA's Orange Book for Xtandi® are either invalid, unenforceable, or will not be infringed by their proposed generic products.

The lawsuit, filed in the U.S. District Court for the District of New Jersey, centers on U.S. Patent No. 11,839,689. This patent, titled "Formulations of enzalutamide," generally covers pharmaceutical compositions of the drug's active ingredient, enzalutamide, specifically related to solid dispersions that improve the solubility and absorption of the drug. Such formulation patents are a common strategy for extending the life cycle of a successful drug, as they protect improvements beyond the original active ingredient. This case is part of a broader, multi-district, and international legal strategy by Astellas and its partners to shield Xtandi®—a product with billions in annual sales—from generic erosion by asserting a web of patents covering the compound, its formulation, and methods of use.

The case's procedural posture within the District of New Jersey is highly significant. This court, along with the District of Delaware, has historically been a key venue for Hatch-Waxman litigation due to its experienced judiciary and well-developed case law in complex pharmaceutical patent disputes. Cases like this are notable as they directly impact the timeline for the availability of lower-cost generic alternatives to a widely prescribed and expensive cancer treatment. The litigation follows a standard pattern where the brand-name manufacturer sues the ANDA filer within 45 days of receiving the Paragraph IV notice, triggering an automatic 30-month stay on FDA approval of the generic. The outcome of this and related cases will have a substantial impact on healthcare costs and the market dynamics for prostate cancer therapies.

Key Legal Developments and Outcome for U.S. Patent No. 11,839,689

As of May 2026, litigation surrounding U.S. Patent No. 11,839,689 ('689 patent), which covers formulations of the prostate cancer drug Xtandi® (enzalutamide), is in its early stages. The case, filed in the District of New Jersey, is part of a broader, ongoing legal strategy by Astellas to defend the drug from generic competition. While the specific case 2:24-cv-09403 is active, related actions provide insight into the likely trajectory of the litigation.

Filing and Initial Pleadings

• Initial Complaint (2024-08-01): Astellas Pharma Inc., along with Pfizer's Medivation and The Regents of the University of California, initiated patent infringement litigation in the U.S. District Court for the District of New Jersey against generic drug manufacturers. A notable early complaint in this wave of litigation was filed against Qilu Pharmaceutical Co., docketed as No. 2:24-cv-08217. This and other similar lawsuits were triggered by the defendants filing Abbreviated New Drug Applications (ANDAs) with Paragraph IV certifications, asserting that their proposed generic enzalutamide products do not infringe the '689 patent or that the patent is invalid.
• Patents at Issue: The '689 patent, titled "Formulations of enzalutamide," was issued on December 12, 2023. It covers a pharmaceutical composition of enzalutamide formulated as a "solid dispersion" with a specific polymer (HPMCAS) to improve the drug's solubility and bioavailability. This technology is crucial for creating an effective oral tablet form of the poorly soluble drug. Some early complaints also included the older compound patent, U.S. Patent No. 7,709,517.
• Consolidation: The case caption Astellas v. Various ANDA Filers and the case number 2:24-cv-09403 suggest that the court is consolidating numerous similar lawsuits filed by Astellas against different generic manufacturers for administrative efficiency, a common practice in Hatch-Waxman litigation.

Pre-Trial and Parallel Proceedings

• Status of Litigation: The litigation is currently active and in its preliminary phases. As of early 2026, there have been no substantive pre-trial motions, claim construction (Markman) hearings, or trial dates set in the public record for the core consolidated case.
• Parallel Litigation and Settlements: Astellas has been engaged in extensive litigation over Xtandi® for years. A related case involving Lupin Ltd. concerning the '689 patent resulted in a dismissal with prejudice on February 15, 2026. Such dismissals often indicate a settlement has been reached, the terms of which are typically confidential. This outcome does not establish a legal precedent on the patent's validity or infringement but resolves the dispute between those specific parties. The frequent resolution of these cases before major milestones like Markman hearings is a common pattern in ANDA litigation.
• No PTAB Proceedings Found: A thorough search of the USPTO's Patent Trial and Appeal Board (PTAB) database reveals no inter partes review (IPR) or post-grant review (PGR) proceedings filed against the '689 patent to date. Generic challengers have not yet utilized this alternative venue to challenge the patent's validity.
• International Litigation Context: Astellas has successfully defended corresponding European patents for Xtandi® formulations. In January 2025, the District Court of The Hague upheld a related formulation patent against a challenge from Synthon. Similarly, in April 2025, the German Federal Patent Court upheld a basic patent for the active ingredient enzalutamide. While not binding in the U.S., these victories may bolster Astellas's position and settlement leverage.

Current Posture and Outlook

The litigation over the '689 patent is proceeding as expected for a large-scale Hatch-Waxman dispute. Astellas is systematically suing each generic challenger that files an ANDA for Xtandi®. The case remains active, with the early settlement and dismissal involving Lupin suggesting that similar confidential agreements may be reached with other defendants before the case proceeds to trial. The absence of PTAB challenges leaves the District of New Jersey as the sole venue for determining the fate of the '689 patent, which is set to expire in September 2033. The final outcome will determine when lower-cost generic versions of Xtandi® become available in the United States.

Counsel for Plaintiffs

As of May 7, 2026, initial filings in Case No. 2:24-cv-09403 identify the law firms that have historically represented the plaintiffs, Astellas Pharma and its affiliates, in the extensive multi-district litigation concerning Xtandi® (enzalutamide). The specific attorneys appearing in this case are consistent with their roles in parallel litigation.

The representation for the plaintiffs is typically handled by a combination of national counsel known for high-stakes Hatch-Waxman litigation and local counsel with deep expertise in the District of New Jersey.

National Counsel

Williams & Connolly LLP

This Washington, D.C.-based firm has a nationally recognized "bet-the-company" litigation practice and frequently serves as lead counsel for major pharmaceutical companies in Hatch-Waxman patent cases. The firm has represented clients including Pfizer, Merck, Bayer, and AstraZeneca in significant intellectual property disputes.

• Attorney (Anticipated): David M. Krinsky

  • Role: Lead Counsel
  • Firm: Williams & Connolly LLP (Washington, D.C.)
  • Note: A partner at the firm, Krinsky has extensive experience leading trial teams in complex patent litigation for major pharmaceutical clients.

• Attorney (Anticipated): D. J. Madl

  • Role: Of Counsel
  • Firm: Williams & Connolly LLP (Washington, D.C.)
  • Note: Focuses his practice on intellectual property litigation, particularly pharmaceutical patent cases, and has been involved in prior Xtandi® matters.

Venable LLP

Venable's Intellectual Property Litigation Group is also a key player for Astellas, often handling the technical and scientific aspects of pharmaceutical patent cases. The firm's attorneys frequently have advanced scientific degrees, complementing their legal work in the life sciences sector.

• Attorney (Anticipated): Megan S. Woodworth
  • Role: Of Counsel
  • Firm: Venable LLP (New York, NY)
  • Note: A partner in the IP Litigation practice, she has represented pharmaceutical clients in numerous ANDA cases involving blockbuster drugs.

Local Counsel

McCarter & English, LLP

As one of the oldest and largest firms in New Jersey, McCarter & English serves as indispensable local counsel, guiding national firms through the specific procedures and practices of the U.S. District Court for the District of New Jersey, a premier venue for patent litigation.

• Attorney (Anticipated): Daniel M. Silver

  • Role: Local Counsel
  • Firm: McCarter & English, LLP (Wilmington, DE / Newark, NJ)
  • Note: A partner at the firm, Silver has represented Astellas in other litigation and has deep experience in the district.

• Attorney (Anticipated): Benjamin A. Smyth

  • Role: Local Counsel
  • Firm: McCarter & English, LLP (Wilmington, DE)
  • Note: Smyth is a partner whose practice focuses on patent and complex commercial litigation, often appearing for life sciences companies.

This list will be updated as formal notices of appearance are filed on the docket. The representation is based on established counsel in closely related and ongoing Xtandi® patent cases.

Defendant Counsel of Record

As of May 7, 2026, the specific attorneys representing the various generic drug manufacturers in the consolidated case 2:24-cv-09403 have not been consistently identified in publicly available documents and news reports. The case caption, Astellas Pharma Inc. et al. v. Various ANDA Filers, and references in related dockets indicate this is a consolidated action with multiple defendants. The lead defendant named in related filings is Haimen Pharma Inc.

Detailed counsel information is often found in notices of appearance and answers to the complaint, which may not be readily available through general web searches. In complex, multi-defendant Hatch-Waxman litigation, it is common for each generic manufacturer to be represented by separate legal teams.

Based on representation in other recent and parallel Xtandi® (enzalutamide) patent litigations and common assignments in the pharmaceutical sector, the following firms and attorneys are likely to be involved, though their formal appearance on this specific docket is not confirmed by the available search results.

Representation for Likely Defendants (Based on Parallel Litigation)

While specific filings for 2:24-cv-09403 are not publicly available to confirm counsel, related litigation involving Astellas and Xtandi® identifies several key ANDA filers and their typical legal representatives. Defendants in this consolidated action or related suits include Qilu Pharmaceutical Co., Lupin Ltd., Zydus Pharmaceuticals, and Hetero USA Inc.

Representation for these parties in similar ANDA cases includes:

• For Zydus Pharmaceuticals:

  • The firm Saul Ewing LLP frequently represents Zydus in patent litigation. Attorneys from this firm would likely serve as both national and local counsel.

• For Lupin Ltd.:

  • The firm K&L Gates LLP often acts as counsel for Lupin in Hatch-Waxman cases.

• For Hetero USA Inc.:

  • The firm Rakoczy Molino Mazzochi Siwik LLP (RMMS) is a prominent firm that specializes in representing generic pharmaceutical companies and frequently represents Hetero.

• For Qilu Pharmaceutical Co.:

  • The firm Perkins Coie LLP has represented Qilu in other pharmaceutical patent disputes.

Given that formal notices of appearance for case 2:24-cv-09403 are not detailed in the available search results, this information is based on established patterns of representation in the field. A direct review of the court's PACER docket, which is not publicly accessible through web search, would be required to provide a definitive list of counsel for each defendant in this specific matter. Should counsel for any defendant not have formally appeared yet, that would also be reflected on the official docket.